Stimulants in 2026: Meth, Cocaine, and the Prescription Shadow
The fourth wave of the crisis is stimulant-driven. And there's still no FDA-approved medication for stimulant use disorder.
Body — 8 lenses: [Science: monoamine release/reuptake (DA, NE, serotonin) — cocaine blocks; meth releases. Biology: hyperthermia, cardiac strain, neurotoxicity (dopamine terminals with chronic high-dose meth), dental effects (“meth mouth” from dry-mouth + acidic diet, not the drug directly). Psychology: the “euphoria gap” after the acute phase, stimulant psychosis in heavy meth use, ADHD/stimulant diagnosis intersection. Policy: Schedule II (meth, cocaine, Rx stimulants); DEA production quotas; Adderall shortage backstory. Trends: stimulant-involved deaths hit 57,500 in 2022, ~70% co-involving fentanyl — the fourth wave. Social: the crack-era racialized policy legacy and current disparities. Treatment: NO FDA-approved medication for stimulant UD; contingency management has the strongest evidence (RCTs 2–4× retention); CBT, community reinforcement, matrix model. Harm reduction: sleep, hydration, avoiding mixing with depressants, safer-use supplies, drug checking.]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Continue reading
More from this section
The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.
Science & MedicineFrance Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.
France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.
Science & MedicineThe FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.
DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.